{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:37:32Z","timestamp":1790861852153,"version":"4.1.0"},"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T00:00:00Z","timestamp":1305158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0019527","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T20:52:03Z","timestamp":1305233523000},"page":"e19527","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":87,"title":["Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response"],"prefix":"10.1371","volume":"6","author":[{"given":"Francina","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Cuy\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olha","family":"Khymenets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mag\u00ed","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,5,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drugalcdep.2005.05.010","article-title":"Cycling in and out of treatment; participation in methadone treatment in NSW, 1990\u20132002.","volume":"81","author":"J Bell","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.","volume":"343","author":"RE Johnson","year":"2000","journal-title":"N Engl J Med"},{"key":"ref3","article-title":"Methadone maintenance: some treatment programs are not effective; greater federal oversight needed. Report to the chairman, Select Committee on Narcotics Abuse and Control, House of Representatives.","year":"1990"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1465-3362.2009.00064.x","article-title":"Persistence of heroin use despite methadone treatment: poor coping self-efficacy predicts continued heroin use.","volume":"28","author":"R Senbanjo","year":"2009","journal-title":"Drug Alcohol Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0b013e318192eb00","article-title":"Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.","volume":"29","author":"AK Elkader","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2006.12.018","article-title":"Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.","volume":"89","author":"J Perez de los Cobos","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.drugalcdep.2008.11.006","article-title":"Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency.","volume":"101","author":"DH Epstein","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0376-8716(01)00171-5","article-title":"Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis.","volume":"65","author":"M Farre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/02791072.1999.10471730","article-title":"Optimizing response to methadone maintenance treatment: use of higher-dose methadone.","volume":"31","author":"S Maxwell","year":"1999","journal-title":"J Psychoactive Drugs"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/clinchem\/38.3.438","article-title":"Methadone concentrations in plasma and their relationship to drug dosage.","volume":"38","author":"K Wolff","year":"1992","journal-title":"Clin Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","article-title":"Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.","volume":"61","author":"CB Eap","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0376-8716(98)00096-9","article-title":"Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program.","volume":"52","author":"M Torrens","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine.","volume":"56","author":"K Kristensen","year":"1995","journal-title":"Life Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.","volume":"80","author":"S Crettol","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03256276","article-title":"Interindividual variability of methadone response: impact of genetic polymorphism.","volume":"12","author":"Y Li","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.","volume":"47","author":"DJ Foster","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","article-title":"Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.","volume":"67","author":"MR Shiran","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","article-title":"Enantiomeric metabolic interactions and stereoselective human methadone metabolism.","volume":"321","author":"RA Totah","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism.","volume":"108","author":"RA Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1046\/j.1360-0443.2000.951217717.x","article-title":"Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility.","volume":"95","author":"K Wolff","year":"2000","journal-title":"Addiction"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00007691-200404000-00019","article-title":"Genetics of the variable expression of CYP3A in humans.","volume":"26","author":"L Wojnowski","year":"2004","journal-title":"Ther Drug Monit"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism.","volume":"11","author":"E Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"P Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics\u2013drug disposition, drug targets, and side effects.","volume":"348","author":"WE Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1503\/cmaj.060664","article-title":"Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.","volume":"174","author":"JW Suh","year":"2006","journal-title":"CMAJ"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clpt.2006.03.012","article-title":"CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.","volume":"80","author":"Y Le Meur","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.","volume":"9","author":"C Iribarne","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.","volume":"76","author":"ED Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/dmd.31.6.742","article-title":"Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.","volume":"31","author":"JS Wang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004714-200204000-00017","article-title":"Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers.","volume":"22","author":"S Begre","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004714-199704000-00010","article-title":"Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.","volume":"17","author":"CB Eap","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00004714-200104000-00016","article-title":"Cytochrome P450 2D6 genotype and methadone steady-state concentrations.","volume":"21","author":"CB Eap","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.","volume":"48","author":"SF Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1365-2125.2003.01851.x","article-title":"A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.","volume":"56","author":"MR Shiran","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2125.1993.tb05666.x","article-title":"Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.","volume":"35","author":"D Wu","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.","volume":"9","author":"H Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.","volume":"78","author":"S Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.","volume":"11","author":"T Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.","volume":"16","author":"JG Gerber","year":"2004","journal-title":"Chirality"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000107104","article-title":"In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites.","volume":"80","author":"S Crettol","year":"2007","journal-title":"Pharmacology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1073\/pnas.84.1.265","article-title":"Expression of a multidrug-resistance gene in human tumors and tissues.","volume":"84","author":"AT Fojo","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.","volume":"97","author":"S Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.","volume":"15","author":"D Wang","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"E515","DOI":"10.1208\/aapsj080361","article-title":"Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1).","volume":"8","author":"D Wang","year":"2006","journal-title":"AAPS J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clpt.2006.09.011","article-title":"ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.","volume":"80","author":"JK Coller","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","article-title":"ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.","volume":"17","author":"O Levran","year":"2008","journal-title":"Hum Mol Genet"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/00952990802122564","article-title":"Pharmacogenetic treatments for drug addiction: alcohol and opiates.","volume":"34","author":"CN Haile","year":"2008","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/ajp.2006.163.4.689","article-title":"Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV.","volume":"163","author":"D Hasin","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1176\/appi.ajp.161.7.1231","article-title":"Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV.","volume":"161","author":"M Torrens","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref50","first-page":"271","article-title":"Estudio de fiabilidad y validez de la versi\u00f3n espa\u00f1ola de la entrevista cl\u00ednica Addiction Severity Index (ASI).","author":"F Gonzalez","year":"2002"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.","volume":"168","author":"AT McLellan","year":"1980","journal-title":"J Nerv Ment Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0731-7085(90)80140-K","article-title":"Determination of morphine and codeine in urine by gas chromatography-mass spectrometry.","volume":"8","author":"A Solans","year":"1990","journal-title":"J Pharm Biomed Anal"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/elps.200305418","article-title":"Chiral separation of methadone, 2-ethylidene- 1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP) by capillary electrophoresis using cyclodextrin derivatives.","volume":"24","author":"T Kelly","year":"2003","journal-title":"Electrophoresis"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/pgs.09.165","article-title":"Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip.","volume":"11","author":"E Cuyas","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.","volume":"319","author":"K Tsuchiya","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/522175","article-title":"Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.","volume":"45","author":"H Gatanaga","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1472-8206.2009.00753.x","article-title":"Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans.","volume":"24","author":"I Arenaz","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5414\/CPP45410","article-title":"Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.","volume":"45","author":"JK Coller","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: human P450 metabolism data.","volume":"34","author":"S Rendic","year":"2002","journal-title":"Drug Metab Rev"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2008.07.017","article-title":"Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.","volume":"55","author":"A Mann","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JCP.0b013e3181a39113","article-title":"Methadone-nicotine interactions in methadone maintenance treatment patients.","volume":"29","author":"AK Elkader","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1369-1600.2010.00274.x","article-title":"CYP2B6 and OPRM1 gene variations predict methadone-related deaths.","volume":"16","author":"H Bunten","year":"2011","journal-title":"Addict Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2125.2004.02221.x","article-title":"Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.","volume":"58","author":"TB Mitchell","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cll.2008.10.003","article-title":"The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.","volume":"28","author":"KK Reynolds","year":"2008","journal-title":"Clin Lab Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF03256337","article-title":"Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery.","volume":"13","author":"WD Wu","year":"2009","journal-title":"Mol Diagn Ther"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1399-6576.2004.00517.x","article-title":"The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.","volume":"48","author":"P Klepstad","year":"2004","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.pnpbp.2008.07.009","article-title":"Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.","volume":"32","author":"S Crettol","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/FPC.0b013e328320a3fd","article-title":"Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution.","volume":"19","author":"A Doehring","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00008571-200412000-00002","article-title":"Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction.","volume":"14","author":"V Yuferov","year":"2004","journal-title":"Pharmacogenetics"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainresrev.2009.09.008","article-title":"Kappa-Opioid receptor signaling and brain reward function.","volume":"62","author":"AW Bruijnzeel","year":"2009","journal-title":"Brain Res Rev"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.57.1.1","article-title":"Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.","volume":"57","author":"MJ Kreek","year":"2005","journal-title":"Pharmacol Rev"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.clpt.6100305","article-title":"No influence of ABCB1 haplotypes on methadone dosage requirement.","volume":"83","author":"S Crettol","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1176\/appi.ps.52.9.1230","article-title":"Patient satisfaction, use of services, and one-year outcomes in publicly funded substance abuse treatment.","volume":"52","author":"MJ Carlson","year":"2001","journal-title":"Psychiatr Serv"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.drugalcdep.2005.11.020","article-title":"Predictors of retention in methadone programs: a signal detection analysis.","volume":"83","author":"SW Villafranca","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archpsyc.1981.01780330033003","article-title":"Treatment for drug abuse. Follow-up outcomes and length of time spent.","volume":"38","author":"DD Simpson","year":"1981","journal-title":"Arch Gen Psychiatry"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.drugalcdep.2005.11.009","article-title":"One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS).","volume":"83","author":"M Teesson","year":"2006","journal-title":"Drug Alcohol Depend"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0019527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T18:11:52Z","timestamp":1712427112000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0019527"}},"subtitle":[],"editor":[{"given":"Ulrich M.","family":"Zanger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,5,12]]},"references-count":76,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0019527","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,12]]}}}